Located in the Quartiere San Lorenzo, the Policlinico Umberto I of Rome is the polyclinic of the Faculty of Medicine and Surgery of the Sapienza Università di Roma.

During the past decade, Policlinico Umberto I conducted 137 clinical trials. In the 10-year time frame, 137 clinical trials started and 43 clinical trials were completed, i.e. on average, 31.4% percent of trials that started reached the finish line to date. In the past 5 years, 60 clinical trials started and 32 clinical trials were completed. i.e. 53.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Policlinico Umberto I" #1 sponsor was "University of Roma La Sapienza" with 28 trials, followed by "Celgene" with 10 trials sponsored, "Pfizer" with 10 trials sponsored, "Amgen" with 7 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 7 trials sponsored. Other sponsors include 135 different institutions and companies that sponsored additional 99 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Policlinico Umberto I" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 3 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Mario Negri Institute for Pharmacological Research" with 2 trials as a collaborator and "Takeda Development Center Americas, Inc." with 2 trials as a collaborator. Other collaborators include 74 different institutions and companies that were collaborators in the rest 84 trials.

According to Clinical.Site data, the most researched conditions in "Policlinico Umberto I" are "Leukemia" (10 trials), "Multiple Myeloma" (7 trials), "Pulmonary Arterial Hypertension" (6 trials), "Coronary Artery Disease" (5 trials) and "Myelodysplastic Syndromes" (4 trials). Many other conditions were trialed in "Policlinico Umberto I" in a lesser frequency.

Most popular intervention types in "Policlinico Umberto I" are "Drug" (124 trials), "Other" (36 trials), "Device" (22 trials), "Procedure" (14 trials) and "Biological" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (36 trials), "Lenalidomide" (5 trials), "etoposide" (5 trials), "idarubicin" (5 trials) and "cytarabine" (4 trials). Other intervention names were less common.

The vast majority of trials in "Policlinico Umberto I" are 190 trials for "All" genders, 10 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 59 active trials in "Policlinico Umberto I". 1 are not yet recruiting, 37 are recruiting, 20 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 93 completed trials in Policlinico Umberto I, undefined suspended trials, and 20 terminated clinical trials to date.

Out of the total trials that were conducted in Policlinico Umberto I, 4 "Phase 1" clinical trials were conducted, 42 "Phase 2" clinical trials and 81 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 34 trials that are defined as “Not Applicable".

Policlinico Umberto I has several departments that took part in Clinical trials: "Policlinico Umberto Primo - Cardiologia B - Cardiologia E Angiologia" - 7 trials, "U.O.C. Neuropsichiatria Infantile" - 4 trials, "Internal and Medical Specialities Department - Policlinico Umberto I" - 3 trials, "Cattedra di Ematologia - Policlinico" - 6 trials, "Policlinico Umberto Primo - Malattie Cardiovascolari A" - 2 trials, "Policlinico Umberto I; Centro Sclerosi Multipla DAI Neuroscienze e Salute Mentale" - 2 trials